WO2021085252A1 - 炎症性肺疾患の予防及び/又は治療剤 - Google Patents
炎症性肺疾患の予防及び/又は治療剤 Download PDFInfo
- Publication number
- WO2021085252A1 WO2021085252A1 PCT/JP2020/039460 JP2020039460W WO2021085252A1 WO 2021085252 A1 WO2021085252 A1 WO 2021085252A1 JP 2020039460 W JP2020039460 W JP 2020039460W WO 2021085252 A1 WO2021085252 A1 WO 2021085252A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- variable region
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention is inflammatory, containing an antibody or antibody fragment having antigen-binding activity against a heterodimer of S100A8 protein (also simply referred to as "S100A8”) and S100A9 protein (also simply referred to as "S100A9”) as an active ingredient.
- S100A8 also simply referred to as "S100A8”
- S100A9 also simply referred to as "S100A9”
- S100 protein is a calcium-binding protein that is expressed specifically in cell types and has two EF-hands, and 20 subfamilies have been confirmed so far.
- S100A8 MRP8, calgranulin A
- S100A9 MRP14, calgranulin B
- S100A8 / A9 Calprotectin
- RA rheumatoid arthritis
- cystic fibrosis Crohn's disease
- ulcerative colitis allergic dermatitis, and infection. It is thought to be involved in the development of chronic inflammatory diseases in humans.
- S100A8 / A9 has the function of attracting distant cancer cells, which is secreted from the lungs, and the function of creating an immunosuppressive environment suitable for cancer cell colonization and proliferation in the lungs.
- EMMPRIN Emprin
- NPTN ⁇ Neuroroplastin- ⁇
- NPTN ⁇ Neuron- ⁇
- MCAM M-cell adhesion molecule
- ALCAM Activated leukocyte cell adhesion molecule
- Patent Document 1 shows that empurin is particularly a receptor for S100A9, and as a result of screening, it is disclosed that mugwort extract, angelica acutiloba extract, dead-nettle extract and the like inhibit the binding between empurin and S100A9.
- Patent Document 2 discloses that as a result of screening, mugwort extract, licorice extract, carrot extract and the like inhibit the binding between NPTN and S100A8.
- S100 inhibitors are useful for the treatment of cancer, autoimmune diseases, inflammatory diseases, neurodegenerative diseases and the like.
- S100A9 has also been reported to be useful as a biomarker for inflammatory bowel disease (Patent Document 4).
- Non-Patent Document 1 reports that it binds to TLR4 and RAGE on the membrane of BV-2 microglial cells and stimulates NF- ⁇ B in BV-2 microglial cells via ERV and JNK to enhance its activity. (Non-Patent Document 1).
- Inflammatory diseases in the lungs that is, diseases such as idiopathic pulmonary fibrosis (IPF) and other idiopathic interstitial pneumonia (IIP) (hereinafter referred to as "inflammatory lung diseases").
- IPF idiopathic pulmonary fibrosis
- IIP interstitial pneumonia
- the number of patients suffering from.) Is steadily increasing.
- idiopathic interstitial pneumonia idiopathic pulmonary fibrosis is a worldwide disease, in which steroids and immunosuppressants do not respond, and the average survival time after acute exacerbation is extremely within 2 months. Poor prognosis.
- Non-Patent Documents 2 and 3 Two types of molecular-targeted therapeutic agents (Pirfenidone and Nintedanib) are known as therapeutic agents for idiopathic pulmonary fibrosis (Non-Patent Documents 2 and 3), but both are symptomatic therapies. The fact is that it cannot be said to be a radical treatment because it cannot be expected to suppress or improve fibrosis.
- Japanese Unexamined Patent Publication No. 2011-47932 Japanese Unexamined Patent Publication No. 2014-59210 International Publication No. WO2015 / 177367 Japanese Unexamined Patent Publication No. 2016-217956
- An object of the present invention is to provide a drug capable of effectively preventing and / or treating inflammatory lung disease. More specifically, to provide a prophylactic and / or therapeutic agent for inflammatory lung disease containing an antibody or antibody fragment having antigen-binding activity as an active ingredient against S100A8 and / or S100A9 known as inflammation-related proteins. Is the subject.
- S100A8 and / or S100A9 and its receptor group EMMPRIN, NPTN ⁇ , MCAM, ALCAM and RAGE
- the present invention comprises the following. 1.
- a prophylactic and / or therapeutic agent for inflammatory lung disease containing an antibody or antibody fragment having antigen-binding activity against a heterodimer of S100A8 and S100A9 proteins as an active ingredient.
- 3. The inflammatory lung disease according to the above item 1 or 2, wherein the antibody or antibody fragment has an antigen-binding activity against the heterodimer of S100A8 and S100A9, and does not have an antigen-binding activity with the S100A8 monomer and / or the S100A9 monomer.
- Prophylactic and / or therapeutic agent 4. The prophylactic and / or therapeutic agent for inflammatory lung disease according to any one of the above items 1 to 3, wherein the antigen-binding activity has a neutralizing affinity. 5. The prophylactic and / or therapeutic agent for inflammatory lung disease according to any one of the above items 1 to 4, wherein the antibody or antibody fragment is a monoclonal antibody or a monoclonal antibody fragment. 6. The prophylactic and / or therapeutic agent for inflammatory lung disease according to item 5 above, wherein the subclass of the monoclonal antibody is one selected from IgG 1 , IgG 2 , IgG 3 and IgG 4. 7.
- the antibody or antibody fragment contains a heavy chain variable region 1 (CDR H1), a heavy chain variable region 2 (CDR H2), and a heavy chain variable region 3 (CDR H3), and a light chain variable region 1 (CDR H3).
- the heavy chain variable region 1 (CDR H1) corresponds to the amino acid sequence shown in SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16 or SEQ ID NO: 19, or SEQ ID NO: 7, 10, 13, 16 or 19, respectively.
- the heavy chain variable region 2 (CDR H2) is for each of the amino acid sequences shown in SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17 or SEQ ID NO: 20, or SEQ ID NO: 8, 11, 14, 17 or 20, respectively. Contains any of the amino acid sequences in which one or more amino acids have been deleted, added, substituted, or inserted.
- the heavy chain variable region 3 (CDR H3) is for each of the amino acid sequences shown in SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18 or SEQ ID NO: 21, or SEQ ID NO: 9, 12, 15, 18 or 21, respectively. Contains any of the amino acid sequences in which one or more amino acids have been deleted, added, substituted, or inserted.
- the light chain variable region 1 (CDR L1) is for each of the amino acid sequences set forth in SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31 or SEQ ID NO: 34, or SEQ ID NO: 22, 25, 28, 31 or 34, respectively. Contains any of the amino acid sequences in which one or more amino acids have been deleted, added, substituted, or inserted.
- the light chain variable region 2 (CDR L2) is for each of the amino acid sequences set forth in SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32 or SEQ ID NO: 35, or SEQ ID NO: 23, 26, 29, 32 or 35, respectively.
- the inflammatory lung according to any one of 1 to 6 above, which comprises an antibody or an antibody fragment as an active ingredient, which comprises any of the amino acid sequences in which one or more amino acids are deleted, added, substituted, or inserted.
- a prophylactic and / or therapeutic agent for the disease 8.
- the heavy chain variable region 1 contains either SEQ ID NO: 7 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 7.
- the heavy chain variable region 2 contains either SEQ ID NO: 8 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 8.
- the heavy chain variable region 3 contains either SEQ ID NO: 9 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 9.
- the light chain variable region 1 (CDR L1) comprises either SEQ ID NO: 22 or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 22.
- the light chain variable region 2 (CDR L2) comprises either SEQ ID NO: 23, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 23.
- the light chain variable region 3 (CDR L3) comprises either SEQ ID NO: 24, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 24.
- the heavy chain variable region 1 contains either SEQ ID NO: 10 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 10.
- the heavy chain variable region 2 contains either SEQ ID NO: 11 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 11.
- the heavy chain variable region 3 (CDR H3) contains either SEQ ID NO: 12 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 12.
- the light chain variable region 1 (CDR L1) comprises either SEQ ID NO: 25, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 25.
- the light chain variable region 2 (CDR L2) comprises either SEQ ID NO: 26, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 26.
- the light chain variable region 3 (CDR L3) comprises either SEQ ID NO: 27, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 27.
- the heavy chain variable region 1 (CDR H1) contains either SEQ ID NO: 13 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 13.
- the heavy chain variable region 2 (CDR H2) contains either SEQ ID NO: 14 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 14.
- the heavy chain variable region 3 (CDR H3) contains either SEQ ID NO: 15 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 15.
- the light chain variable region 1 (CDR L1) comprises either SEQ ID NO: 28, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 28.
- the light chain variable region 2 (CDR L2) comprises either SEQ ID NO: 29, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 29.
- the light chain variable region 3 (CDR L3) comprises either SEQ ID NO: 30, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 30.
- the heavy chain variable region 1 (CDR H1) contains either SEQ ID NO: 16 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 16.
- the heavy chain variable region 2 (CDR H2) contains either SEQ ID NO: 17 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 17.
- the heavy chain variable region 3 (CDR H3) contains either SEQ ID NO: 18 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 18.
- the light chain variable region 1 (CDR L1) comprises either SEQ ID NO: 31 or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 31.
- the light chain variable region 2 (CDR L2) comprises either SEQ ID NO: 32, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 32.
- the light chain variable region 3 (CDR L3) comprises either SEQ ID NO: 33, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 33.
- the prophylactic and / or therapeutic agent for inflammatory lung disease according to item 7 above. 12.
- the heavy chain variable region 1 contains either SEQ ID NO: 19 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 19.
- the heavy chain variable region 2 contains either SEQ ID NO: 20 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 20.
- the heavy chain variable region 3 contains either SEQ ID NO: 21 or an amino acid sequence in which one or more amino acids are deleted, added, substituted, or inserted in the amino acid sequence shown in SEQ ID NO: 21.
- the light chain variable region 1 comprises either SEQ ID NO: 34, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 34.
- the light chain variable region 2 comprises either SEQ ID NO: 35, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 35.
- the light chain variable region 3 (CDR L3) comprises either SEQ ID NO: 36, or an amino acid sequence in which one or more amino acids have been deleted, added, substituted, or inserted in the amino acid sequence set forth in SEQ ID NO: 36.
- the prophylactic and / or therapeutic agent for inflammatory lung disease according to item 7 above. 13. Expression of NF- ⁇ B and pulmonary fibroblasts, which block the interaction between S100A8 and / or S100A9 and its receptor, RAGE, and induce the expression of inflammatory cytokines, which are transcription factors downstream of RAGE. Any of 1 to 12 above, which is characterized by suppressing the proliferation of activated fibroblasts, suppressing the proliferation of activated fibroblasts, and further suppressing the differentiation of activated fibroblasts into myofibroblasts.
- the prophylactic and / or therapeutic agent for inflammatory lung disease according to. 14. The prophylactic and / or therapeutic agent for inflammatory lung disease according to any one of the preceding paragraphs 1 to 13, as a prophylactic and / or therapeutic agent for COVID-19.
- inflammatory lung disease is effective by blocking the interaction between S100A8 and / or S100A9 and RAGE, which is one of its receptors.
- RAGE is a major receptor for S100A8 / A9 in the lung, is highly expressed in alveolar epithelial cells that cause inflammatory lung disease, and serves as a starting point for pathological conditions related to inflammatory lung disease.
- the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention is a transcription factor that blocks the interaction between S100A8 and / or S100A9 and RAGE, which is one of its receptors, and is located downstream of RAGE.
- the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention can effectively prevent and / or treat inflammatory lung disease.
- thermodynamic stability about the purified S100A8 / A9 heterodimer, S100A8 monomer and S100A9 monomer.
- Reference example 1 It is a figure which shows the result of having confirmed the neutralizing ability with respect to S100A8 / A9 heterodimer, S100A8 or S100A9 by the ELISA method about 10 clones selected from the hybridoma for anti-S100A8 / A9 antibody production.
- Example 1 Using human keratinocytes in which inflammatory cytokines are strongly induced by S100A8 / A9, 10 clones selected from hybridomas for anti-S100A8 / A9 antibody production were subjected to TNF- ⁇ , IL-6 and IL-8 expression inhibitory effects. It is a figure which shows the confirmed result.
- Example 2 It illustrates the Fab domain structure of the chimeric antibody by fusing human IgG 2 -Fc portions of anti-S100A8 / A9 monoclonal antibody (clone No.45).
- Example 4 It is a figure which shows the proliferation enhancement of mouse fibroblast by S100A8 / A9.
- Example 5 It is a figure which shows the proliferation enhancement of human fibroblast by S100A8 / A9.
- Example 5 It is a figure which shows the evaluation result of S100A8 / A9-dependent NF- ⁇ B signal activation in fibroblast.
- Example 6 It is a figure which shows the evaluation result of the NF- ⁇ B signal suppression by an anti-S100A8 / A9 antibody ( ⁇ -S100A8 / A9 antibody) in a fibroblast.
- Example 6 It is a figure which shows the evaluation result of the expression induction of ⁇ -SMA by S100A8 / A9 in human lung fibroblast, and the ability of anti-S100A8 / A9 antibody ( ⁇ -S100A8 / A9 antibody) to suppress S100A8 / A9 inducible ⁇ -SMA expression. .. (Example 7) Induction of ⁇ -SMA and collagen expression by S100A8 / A9 in mouse fibroblasts and evaluation of S100A8 / A9-inducible ⁇ -SMA and collagen expression inhibitory ability by anti-S100A8 / A9 antibody ( ⁇ -S100A8 / A9 antibody) It is a figure which shows the result.
- Example 7 It is a figure which shows the experimental protocol for confirming the lung injury suppression effect by the anti-S100A8 / A9 antibody using the bleomycin intratracheal administration pulmonary fibrosis model.
- Example 8 It is a figure which shows the concentration-dependent weight loss suppression effect by administration of anti-S100A8 / A9 antibody in the bleomycin intratracheal administration pulmonary fibrosis model.
- Example 8) It is a photographic figure which shows the CT scan result of the lung by the anti-S100A8 / A9 antibody administration in the bleomycin intratracheal administration pulmonary fibrosis model.
- Example 8 It is a figure which shows the graph which quantified the high density area area of the lung by the anti-S100A8 / A9 antibody administration in the bleomycin intratracheal administration pulmonary fibrosis model.
- Example 8 It is a figure which shows the survival rate of the mouse by the anti-S100A8 / A9 antibody administration in the bleomycin intratracheal administration pulmonary fibrosis model.
- Example 8) It is a figure which shows the effect of the anti-S100A8 / A9 antibody to suppress the expression of TMPRSS2 in human lung cells.
- Example 9 It is a figure which shows the graph which quantified the high density area area of the lung by the anti-S100A8 / A9 antibody administration in the bleomycin intratracheal administration pulmonary fibrosis model.
- the present invention relates to a prophylactic and / or therapeutic agent for inflammatory lung disease, which contains an antibody or antibody fragment having antigen-binding activity against S100A8 / A9 as an active ingredient.
- the "antibody having antigen-binding activity against S100A8 / A9” contained in the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention is referred to as "anti-S100A8 / A9 antibody", and is separately referred to as “antibody of the present invention”. It may also be called.
- “S100A8 / A9” means a complex of S100A8 and S100A9, and may be referred to as "S100A8 / A9 heterodimer" in some cases.
- the antibody of the present invention is an antibody prepared using the S100A8 / A9 heterodimer as an antigen, and has an antigen-binding activity against the S100A8 / A9 heterodimer.
- the anti-S100A8 / A9 antibody preferably has a higher antigen-binding activity to the S100A8 / A9 heterodimer than the antigen-binding activity to the S100A8 monomer.
- the anti-S100A8 / A9 antibodies those having an antigen-binding activity against the heterodimer of S100A8 and S100A9, and further having no antigen-binding activity with the S100A8 monomer and / or the S100A9 monomer are more preferable.
- the antigen-binding activity may be any generally interpreted antigen-binding activity, and is not particularly limited, and examples thereof include neutralizing antibody affinity.
- the anti-S100A8 / A9 antibody those having a higher neutralizing antibody affinity for the heterodimer of S100A8 and S100A9 than the neutralizing antibody affinity for the S100A8 monomer are preferable, and further, those having a higher neutralizing antibody affinity for the heterodimer of S100A8 and S100A9 are preferable. Those having a neutralizing antibody affinity for the heterodimer and not having a neutralizing antibody affinity with the S100A8 monomer and / or the S100A9 monomer are more preferable.
- the antibody of the present invention is used in the broadest sense, and includes monoclonal antibody, polyclonal antibody, chimeric antibody and multispecific antibody as long as it exhibits the antigen-binding activity shown above.
- the antibody of the present invention can contain a heavy chain variable region (VH-CDR) and / or a light chain variable region (VL-CDR) or a fragment thereof.
- the class of antibody of the present invention refers to the type of constant domain or constant region provided in the heavy chain (H chain) of an antibody, and examples thereof include IgA, IgD, IgE, IgG and IgM.
- the class of antibody in the present specification is not particularly limited, but IgG is most preferable. Examples of the IgG subclass include IgG 1 , IgG 2 , IgG 3 , IgG 4, and the like, and IgG 1 or IgG 2 is preferable.
- the "antibody fragment" of an antibody having antigen-binding activity against the S100A8 / A9 heterodimer has a portion of the antibody structure and retains the activity of the antibody of the present invention. Anything is fine.
- the structure of the antibody fragment includes a fragment of the antigen binding site of the antibody, and examples thereof include a heavy chain variable region (VH-CDR) and / or a light chain variable region (VL-CDR) and a fragment thereof.
- VH-CDR heavy chain variable region
- VL-CDR light chain variable region
- Fv, Fab, Fab', Fab'-SH, F (ab') 2 or a combination thereof can be exemplified.
- the antibody of the present invention may be a human antibody, a humanized antibody, or a chimeric antibody.
- Human antibody refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by humans or human cells, or an antibody derived from a non-human source using the human antibody repertoire or other human antibody coding sequences.
- the amino acid sequence of VH-CDR and / or VL-CDR contained in the antibody of the present invention can include, for example, the amino acid sequence specified by the following SEQ ID NO:.
- the heavy chain variable region 1 (CDRH1) can contain any of the amino acid sequences shown in SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16 or SEQ ID NO: 19.
- the heavy chain variable region 2 (CDR H2) can contain any of the amino acid sequences shown in SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17 or SEQ ID NO: 20.
- the heavy chain variable region 3 (CDR H3) can contain any of the amino acid sequences shown in SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18 or SEQ ID NO: 21.
- the light chain variable region 1 (CDR L1) can contain any of the amino acid sequences shown in SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31 or SEQ ID NO: 34.
- the light chain variable region 2 (CDR L2) region can contain any of the amino acid sequences shown in SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32 or SEQ ID NO: 35.
- the light chain variable region 3 can contain any of the amino acid sequences shown in SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 33 or SEQ ID NO: 36.
- the amino acid sequence information of each of the above regions is also included in the scope of rights.
- an anti-S100A8 / A9 antibody containing those amino acid sequences as long as it shows antigen-binding activity against the S100A8 / A9 heterodimer.
- the antibody fragment is also included in the scope of rights of the present invention.
- the antibody or antibody fragment of the present invention can be prepared according to a conventional method using the above S100A8 / A9 heterodimer antigen.
- the antibody of the present invention is a monoclonal antibody
- a mammal such as a mouse or rat
- lymphocytes are collected from the animal, and the hybridoma is fused with myeloma cells according to a conventional method.
- Hybridomas can be prepared to produce anti-S100A8 / A9 antibodies.
- Mammalian immunity can follow conventional methods.
- a mixture of the above S100A8 / A9 heterodimer antigen and an adjuvant can be used as an immunogen to immunize an animal.
- the adjuvant is not particularly limited, and examples thereof include Freund complete adjuvant and Freund incomplete adjuvant.
- the method of administering the immunogen for immunization may be any of methods known per se, for example, subcutaneous injection, intraperitoneal injection, intravenous injection, intramuscular injection, but subcutaneous injection or intraperitoneal injection is preferable. Immunization may be performed once or multiple times at appropriate intervals, preferably multiple times at intervals of 1 to 5 weeks. It is possible to obtain the desired monoclonal antibody-producing cells by confirming the binding property of the culture supernatant of the prepared hybridoma to the S100A8 / A9 heterodimer by an ELISA method or the like and repeating the cloning operation of the antibody-producing hybridoma. it can. As a method for producing a humanized antibody, a method known per se can be applied.
- Total RNA can be purified from hybridoma cells that produce antibodies according to a standard method, and subsequently cDNA can be synthesized.
- Each gene fragment can be obtained by performing PCR on the antibody genes of the full length heavy chain (H chain) and light chain (L chain) from the obtained cDNA using the respective primers and amplifying them.
- the gene for the antibody By ligating the obtained gene fragment to an expression vector, the gene for the antibody can be cloned.
- the base sequence of the plasmid vector encoding them can be confirmed, and the amino acid sequence of the antibody can be determined based on the base sequence.
- an antibody may be prepared by a gene recombination method or an antibody may be prepared by a synthetic method.
- an antibody is produced by a gene recombination method, it can be produced, for example, by the method described in International Publication No. WO2017 / 061354.
- amino acid sequence When producing an antibody by a gene recombination method, for example, genetic information encoding each amino acid that identifies CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 can be used.
- amino acid sequence include any of the amino acid sequences shown in SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16 or SEQ ID NO: 19 in CDR H1.
- SEQ ID NO: 8 any of the amino acid sequences shown in SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17, or SEQ ID NO: 20 can be mentioned.
- any of the amino acid sequences shown in SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, or SEQ ID NO: 21 can be mentioned.
- any one of the amino acid sequences shown in SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31 or SEQ ID NO: 34 can be mentioned.
- any of the amino acid sequences shown in SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32 or SEQ ID NO: 35 can be mentioned.
- the present invention also includes base sequence information encoding each amino acid that specifies the above-specified CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3, and base sequence information of a complementary strand thereof.
- the present invention has a base sequence in which the anti-S100A8 / A9 antibody of the present invention can be produced even if one or more nucleotides are substituted, deleted, added or inserted. Such base sequence information is also included in the scope of rights of the present invention.
- the antibody screening method and antibody evaluation confirmation method of the present invention will be specifically described in Reference Examples, Examples and Experimental Examples described later, but the following methods can also be applied, for example.
- hybridomas expressing multiple types of S100A8 / A9 neutralizing antibody candidates can be acclimated to serum-free culture and prepared in large quantities for in vitro and in vivo experiments.
- the culture supernatant of each clone can be collected and the antibody can be purified.
- a method known per se or any method developed in the future can be applied.
- the antibody can be recovered by performing affinity chromatography. Specifically, affinity purification using Protein A / G is common, and a column suitable for each animal species and antibody subclass can be used. ..
- the purity test of the purified antibody can be performed by a method known per se, for example, by CBB staining.
- the S100A8 / A9 adsorptive decoy protein preparation (exEMMPRIN-Fc, exNPTN ⁇ -Fc, exMCAM-Fc, exRAGE-Fc, exALCAM-Fc), which is a receptor for S100A8 / A9, is used.
- EMMPRIN-Fc exNPTN ⁇ -Fc
- exMCAM-Fc exRAGE-Fc
- exALCAM-Fc exALCAM-Fc
- inflammatory lung disease refers to idiopathic / chronic inflammatory lung disease, bronchial asthma, which can be prevented and / or treated by the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention.
- Means all inflammatory lung diseases such as interstitial pneumonia, for example, idiopathic interstitial pneumonia (IIP: idiopathic organizing pneumonia, non-specific interstitial) such as idiopathic pulmonary fibrosis (IPF).
- IIP idiopathic interstitial pneumonia
- IPF idiopathic pulmonary fibrosis
- the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention can effectively prevent and / or treat the inflammatory lung disease based on the mechanism of action described later.
- the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention may be administered topically or systemically.
- the antibody used in the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention has a pharmaceutically acceptable purity together with an optionally pharmaceutically acceptable carrier, excipient or stabilizer. It is also possible to use it in combination with other antibodies other than the above antibody. It is also optional to use a lyophilized preparation or a water-soluble form for storage.
- a pharmaceutically acceptable, sterile, aqueous or non-aqueous solution, diluent, suspension and It may contain an emulsion.
- non-aqueous diluents examples include propylene glycol, polyethylene glycol, vegetable oils such as olive oil and organic ester compositions such as ethyloleate, which are suitable for injection.
- the aqueous carrier may include water, an alcoholic aqueous solution, an emulsion, a suspension, a saline solution and a buffering medium.
- Parenteral carriers may include sodium chloride solution, Ringer dextrose, dextrose and sodium chloride, Ringer lactic acid and binding oil.
- Intravenous carriers may include, for example, liquid supplements, nutrients and electrolytes (eg, those based on Ringer dextrose).
- the prophylactic and / or therapeutic agents for inflammatory lung disease of the present invention can further include preservatives and other additives such as antimicrobial compounds, antioxidants, chelating agents and inert gases.
- preservatives and other additives such as antimicrobial compounds, antioxidants, chelating agents and inert gases.
- the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention has one or more bioactive compounds, preferably complementary activities that do not adversely affect each other, as required, and is itself.
- bioactive compounds preferably complementary activities that do not adversely affect each other, as required, and is itself.
- one or more of other agents capable of reducing side effects can be used in combination.
- the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention contains a therapeutically effective amount of anti-S100A8 / A9 antibody.
- a therapeutically effective amount is an amount effective in achieving the desired therapeutic result at the required dose and duration.
- the therapeutically effective amount may be set in consideration of the disease state, age, sex and body weight of the individual, and the efficacy of the drug that induces a desired reaction in the individual.
- the prophylactic and / or therapeutic agents for inflammatory lung disease of the present invention are used in single or divided doses, usually every 24, 12, 8, 6, 4 or 2 hours or in any combination to initiate treatment. Later, usually 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, At least once on days 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40, or also 1, 2, 3, 4, Approximately 0.1 per day at least once in the 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th or 20th week, or any combination thereof.
- ⁇ 100 mg / kg body weight for example 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg / kg body weight antibody amount It can be used as a daily dose.
- the full-length S100A8 or the full-length S100A9 was incorporated into pET21, prepared from Escherichia coli by the same method as above, and purified (see Futami J. et al. (2016)).
- the naturally occurring S100A8 / A9 heterodimer (simply abbreviated as “A8-A9 heterodimer”) is thermodynamically stable, but S100A8 (simply abbreviated as "A8") and S100A9 (simply abbreviated as "A8"). Since each of them forms a homodimer (abbreviated as "A9"), it is difficult to prepare a stable heterodimer of S100A8 / A9 even if S100A8 and S100A9 are mixed.
- the S100A8 / A9 heterodimer prepared by the method of this reference example has high stability and can be used as the S100A8 / A9 heterodimer antigen prepared in the examples described later.
- Example 1 Preparation of anti-S100A8 / A9 monoclonal antibody
- preparation of the anti-S100A8 / A9 monoclonal antibody used in the following examples and experimental examples will be described.
- the anti-S100A8 / A9 monoclonal antibody of this example was prepared using the S100A8 / A9 heterodimer prepared in the above (Reference Example 1) as an antigen.
- the anti-S100A8 / A9 monoclonal antibody of this example uses the S100A8 / A9 heterodimer prepared in the above (Reference Example 1) as an antigen, and uses the monoclonal antibody contract service, Genostaff (Nippon Genetics). And made. Mice (BALB / c) were used as immunized animals, and Titer-MAX was used as an adjuvant for antigen immunization. According to the conventional method, the spleen of an immune animal and mouse myeloma cells (P3U1) were fused with polyethylene glycol (PEG1500) to prepare a hybridoma, and 160 clones were obtained.
- PEG1500 polyethylene glycol
- Example 2 Screening of neutralizing antibody
- the effect of the monoclonal antibody produced from the 160 clone hybridomas prepared and selected in Example 1 on the production amount of S100A8 / A9-inducible inflammatory cytokines was exerted. confirmed.
- human keratinocytes in which inflammatory cytokines are strongly induced by S100A8 / A9 the inhibitory effect of each antibody on the S100A8 / A9 signal was evaluated using the mRNA expression level of the inflammatory cytokines as an index.
- each anti-S100A8 / A9 monoclonal antibody purified by Protein G column from 1 mL of the hybridoma culture supernatant of 30 ng / mL purified S100A8 / A9 and 160 clones was added to keratinocytes (Normal Human Keratinocytes: NHK).
- the cells were collected after culturing at 37 ° C. for 3 hours, and the expression levels of TNF- ⁇ , IL-6, and IL-8 were analyzed by real-time quantitative PCR (qPCR).
- qPCR Real-time quantitative PCR analysis was performed using the LightCycler rapid thermal cycler system (ABI 7900HT; Applied Biosystems). Measurements were made using forward (Fwd) and reverse (Rev) primers consisting of the following nucleotide sequences.
- Fwd for TNF ⁇ measurement GACAAGCCTGTAGCCCATGT (SEQ ID NO: 1) Rev: TCTCAGCTCCACGCCATT (SEQ ID NO: 2)
- IL-6 measurement Fwd: CTTCCCTGCCCCAGTACC (SEQ ID NO: 3) Rev: CTGAAGAGGTGAGTGGCTGTC (SEQ ID NO: 4)
- IL-8 measurement Fwd: AGACAGCAGAGCACACAAGC (SEQ ID NO: 5) Rev: AGGAAGGCTGCCAAGAGAG (SEQ ID NO: 6)
- Example 3 Amino acid sequence of variable region of selected antibody For five types of anti-S100A8 / A9 monoclonal antibodies (clone No .: 45, 85, 235, 258 and 260) selected from the above screening, heavy chain and light chain. The sequence of the variable region of was analyzed.
- VH-CDR Clone No.45 CDR H1: SYWMQ (SEQ ID NO: 7) Clone No.45: CDR H2: AIYPGDGDTRDTQKFKG (SEQ ID NO: 8) Clone No.45: CDR H3: MAGYNYDNDY (SEQ ID NO: 9) Clone No.85: CDR H1: SGYNWH (SEQ ID NO: 10) Clone No.85: CDR H2: YIQYSGSTNYNPSLKS (SEQ ID NO: 11) Clone No.85: CDR H3: ALRYDYSWFAY (SEQ ID NO: 12) Clone No.235: CDR H1: NFWMN (SEQ ID NO: 13) Clone No.235: CDR H2: QIYPGKSDTNYNGKFKG (SEQ ID NO: 14) Clone No.235: CDR H3: WGAYYKYGGSYFDY (SEQ ID NO: 15) Clone No.258: CDR H1
- Example 4 Preparation of anti-S100A8 / A9 chimeric antibody
- a chimeric antibody was prepared by fusing a human IgG 2-Fc moiety to the Fab domain of an anti-S100A8 / A9 monoclonal antibody (clone No. 45). Sequence analysis and CDR analysis of the heavy chain and light chain variable regions of the anti-S100A8 / A9 monoclonal antibody (clone No. 45), and a stable expression vector for CHO cells incorporating the variable region of Human IgG 2 and the recombinant sequence was obtained.
- the antibody was prepared and transduced into CHO cells by combining the genes of the human IgG 2- Fc moiety to stably prepare an anti-S100A8 / A9 chimeric antibody (see FIG. 7).
- Antibodies were prepared by the method described in WO 2017/061354.
- fibroblasts cultured in GIBCO (R) DMEM / F-12 (Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12) medium containing 10% fetal bovine serum (FBS) were placed in 6-well plates 2 ⁇ 10 5 each. Sown in cells / well. After 24 hours of culturing, the medium was replaced with a serum-free medium.
- the medium was replaced with a medium containing 0.5% FBS, and S100A8 / A9 at each concentration was added.
- EdU was added, and after 1 hour, the cells stained with EdU were confirmed under a microscope. As shown in FIGS. 8 and 9, the addition of S100A8 / A9 confirmed that the S100A8 / A9 concentration increased to 100 ng / mL, and the growth rate decreased at 1000 ng / mL.
- Fibroblasts of B6 mice (WT) cultured in GIBCO (R) DMEM / F-12 medium containing 10% FBS were seeded in 5 ⁇ 10 5 cells in a 10 cm petri dish and replaced with serum-free medium 24 hours later. After culturing for another 6 hours, the cells were replaced with a medium containing 0.5% FBS, control buffer (PBS) or 100 ng / mL S100A8 / A9 was added, and after 0, 1, 6, 24, and 48 hours, the cells were washed with PBS and then collected. did. The cells were suspended in 100 ⁇ L of Thermo Scientific M-PER (Mammalian Protein Extraction Reagent) to prepare cell lysate.
- Thermo Scientific M-PER Mammalian Protein Extraction Reagent
- Biotin-labeled NF- ⁇ B binding DNA probe (NF- ⁇ B consensus binding motif 5'-agttgaGGGGACTTTCCcaggc-3' (SEQ ID NO: 37)) and cell lysate are mixed, reacted on ice for 30 minutes, and then native gel electrophoresis (Native-). PAGE) was performed, the gel was transferred to a nitrocellulose membrane, cross-linked by UV irradiation, blocked, reacted with Avidin-HRP, and chemiluminescence was detected. As a result, it was confirmed that the activity of NF- ⁇ B was induced in a S100A8 / A9-dependent manner, and that the activity was maximized 6 hours after the addition (see FIG. 10).
- a gel shift assay was performed using fetal fibroblasts (MEF) derived from B6 mice (WT) and RAGE knockout B6 mice (RAGE-/-) and fibroblasts derived from human normal fetal lung tissue (MRC-5).
- MEF fetal fibroblasts
- RAGE-/- RAGE knockout B6 mice
- fibroblasts derived from human normal fetal lung tissue
- control buffer 100 ng / mL S100A8 / A9, 1 ⁇ g / mL IgG (control), or 1 ⁇ g / mL anti-S100A8 / A9 antibody ( ⁇ -S100A8 / A9 antibody).
- control buffer 100 ng / mL S100A8 / A9, 1 ⁇ g / mL IgG (control), or 1 ⁇ g / mL anti-S100A8 / A9 antibody ( ⁇ -S100A8 / A9 antibody).
- NF- ⁇ B activity was observed in a system free of anti-S100A8 / A9 antibody.
- suppression of NF- ⁇ B activity was confirmed in the system containing the anti-S100A8 / A9 antibody (see FIG. 11).
- fetal fibroblasts (MEF) derived from RAGE knockout B6 mice (RAGE-/-) stimulation of the 100A8 / A9 complex was confirmed to slightly activate the NF- ⁇ B signal.
- the slight activation of the NF- ⁇ B signal was considered to be due to receptors other than RAGE (EMMPRIN, NPTN ⁇ , MCAM, ALCAM identified by the present inventor as S100A8 / A9 receptors). Activation of the NF- ⁇ B signal was completely suppressed in the anti-S100A8 / A9 antibody.
- ⁇ -S100A8 / A9 antibody means anti-S100A8 / A9 monoclonal antibody (clone No. 45), and IgG (control) means mouse IgG Isotype control. The same applies to the ⁇ -S100A8 / A9 antibody and IgG (control) shown in the following examples.
- Example 7 Induction of expression of ⁇ -SMA and collagen (collagen) by S100A8 / A9 in fibrosis and evaluation of S100A8 / A9-inducible ⁇ -SMA and collagen expression inhibitory ability by anti-S100A8 / A9 antibody
- the differentiation of activated fibrosis into myofibroblasts induces excessive deposition of collagen and extracellular matrix components, thereby exacerbating pulmonary fibrosis.
- Nintedanib approved for the treatment of idiopathic pulmonary fibrosis (IPF), inhibits fibroblast proliferation and differentiation into myofibroblasts.
- ⁇ -SMA smooth muscle actin
- FIGS. 12 and 13 After culturing for another 6 hours, the cells were replaced with a medium containing 0.5% FBS, and control buffer, 100 ng / mL S100A8 / A9, 1 ⁇ g / mL IgG (control) or 1 ⁇ g / mL anti-S100A8 / A9 antibody are shown in FIGS. 12 and 13. The cells were added in combination, and cell lysates were collected after 48 hours.
- Fetal fibroblasts derived from B6 mice (WT) and RAGE knockout B6 mice (RAGE-/-) are specifically targeted for collagen chains denatured by anti- ⁇ -SMA monoclonal antibody, collagenase and mechanical damage to connective tissue. Proteins were detected using an anti-Tubulin antibody as a binding biolabeled probe and control.
- S100A8 / A9 is a risk factor that induces the differentiation of fibroblasts into myofibroblasts. Then, the inhibitory effect of the anti-S100A8 / A9 antibody on the expression of ⁇ -SMA and collagen, which are markers of myofibroblasts, was confirmed (see FIGS. 12 and 13). These results suggest that the anti-S100A8 / A9 antibody has a preventive effect on pulmonary fibrosis.
- Example 8 Intratracheal administration of bleomycin Pulmonary injury suppressing effect of anti-S100A8 / A9 antibody in pulmonary fibrosis model The pulmonary injury suppressing effect of anti-S100A8 / A9 antibody in bleomycin-induced pulmonary fibrosis model was confirmed. .. According to the protocol shown in FIG. 14, 50 ⁇ l of PBS containing 1.0 mg / kg bleomycin per mouse body weight was administered into the trachea of 7 C57BL / 6J females (8 weeks old) in each group to prepare lung injury model mice. .. One to two hours after the administration of bleomycin, PBS buffer (control group: 0 ⁇ g) or 200 ⁇ g and 500 ⁇ g of anti-S100A8 / A9 antibody was intravenously administered to the tail vein.
- PBS buffer control group: 0 ⁇ g
- 500 ⁇ g of anti-S100A8 / A9 antibody was intravenously administered to the tail vein.
- FIG. 17 shows a graph in which the high-density area of the CT scan image (the region confirmed as white in the lung tissue of the CT scan image) is quantified by imaging.
- the 500 ⁇ g administration group of anti-S100A8 / A9 antibody a significant inhibitory effect was observed on lung tissue injury and fibrosis 21 days after bleomycin administration.
- the survival rate of mice in this experiment is shown in FIG.
- mice No dead mice were confirmed in the 500 ⁇ g anti-S100A8 / A9 antibody group, but 5 out of 7 mice died in the antibody-non-antibody group.
- the number "Number at risk” shown in the lower part of FIG. 18 indicates the number of surviving mice.
- the anti-S100A8 / A9 antibody showed an excellent therapeutic effect on pulmonary fibrosis even in the in vivo system using the intratracheal administration pulmonary fibrosis model.
- Example 9 Effect of anti-S100A8 / A9 antibody on suppressing TMPRSS2 expression in human lung cells As shown in Example 8, it was found that the anti-S100A8 / A9 antibody shows an excellent therapeutic effect on pulmonary fibrosis. Subsequently, while investigating the further pharmacological action of the anti-S100A8 / A9 antibody, TMPRSS2, which is one of the host proteolytic enzymes expressed in the respiratory epithelium, was found to be SARS-CoV-2. Focusing on one of the important proteins in the infection, we investigated the effect of anti-S100A8 / A9 antibody on TMPRSS2 expression.
- the normal part of the lung tissue excised at the time of human lung cancer surgery was cut into pieces with a diameter of about 3 mm and treated with collagenase at 4 ° C. for 24 hours in a serum-free medium to disperse lung tissue-derived cells.
- a serum-free medium After suspending the cells thus obtained in a serum-free medium, 1 ⁇ g / mL of purified S100A8 / A9 and 10 ⁇ g / mL anti-S100A8 / A9 antibody (clone No. 45) or 10 ⁇ g / mL control IgG was added. The cells were collected after culturing at 37 ° C.
- TMPRSS2 can activate SARS-CoV-2 bound to the ACE2 receptor present on the cell surface and enhance the high rate of cell invasion (cleavage activation of Spike protein in the outer membrane of the virus). found.
- S100A8 / A9 significantly induced the expression of TMPRSS2 in human lung cells, and the anti-S100A8 / A9 antibody was found. , It was found that the induced expression was remarkably suppressed.
- the anti-S100A8 / A9 antibody not only suppresses cytokine storms induced by SARS-CoV-2 virus in the treatment of COVID-19, but also protects against SARS-CoV-2 infection by suppressing TMPRSS2 expression. It was suggested to be useful.
- the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention is S100A8 / A9 whose expression is increased with inflammatory lung disease, and alveolar epithelial cells which are receptors thereof and are the origin of pathological conditions.
- S100A8 / A9 whose expression is increased with inflammatory lung disease
- alveolar epithelial cells which are receptors thereof and are the origin of pathological conditions.
- the prophylactic and / or therapeutic agent for inflammatory lung disease of the present invention can also be suitably used for the prophylactic agent and / or treatment of COVID-19.
- the industrial applicability of the present invention, which exerts such remarkable effects, is immeasurable.
Abstract
Description
1.S100A8及びS100A9タンパク質のヘテロダイマーに対して抗原結合活性を有する抗体又は抗体断片を有効成分として含む炎症性肺疾患の予防及び/又は治療剤。
2.抗体又は抗体断片が、S100A8モノマーに対する抗原結合活性よりも高い抗原結合活性を有することを特徴とする、前項1に記載の炎症性肺疾患の予防及び/又は治療剤。
3.抗体又は抗体断片が、S100A8及びS100A9のヘテロダイマーに対し、抗原結合活性を有し、S100A8モノマー及び/又はS100A9モノマーとは抗原結合活性を有さない、前項1又は2に記載の炎症性肺疾患の予防及び/又は治療剤。
4.抗原結合活性が中和親和性である、前項1~3のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
5.抗体又は抗体断片が、モノクローナル抗体又はモノクローナル抗体断片である、前項1~4のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
6.モノクローナル抗体のサブクラスが、IgG1、IgG2、IgG3及びIgG4より選択されるいずれかである、前項5に記載の炎症性肺疾患の予防及び/又は治療剤。
7.抗体又は抗体断片が、重鎖可変領域1(CDR H1)、重鎖可変領域2(CDR H2)及び重鎖可変領域3(CDR H3)を含む重鎖可変領域と、軽鎖可変領域1(CDR L1)、軽鎖可変領域2(CDR L2)及び軽鎖可変領域3(CDR L3)を含む軽鎖可変領域を含み、
重鎖可変領域1(CDR H1)が、配列番号7、配列番号10、配列番号13、配列番号16又は配列番号19に示すアミノ酸配列、あるいは配列番号7、10、13、16又は19それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号8、配列番号11、配列番号14、配列番号17又は配列番号20に示すアミノ酸配列、あるいは配列番号8、11、14、17又は20それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号9、配列番号12、配列番号15、配列番号18又は配列番号21に示すアミノ酸配列、あるいは配列番号9、12、15、18又は21それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号22、配列番号25、配列番号28、配列番号31又は配列番号34に示すアミノ酸配列、あるいは配列番号22、25、28、31又は34それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号23、配列番号26、配列番号29、配列番号32又は配列番号35に示すアミノ酸配列、あるいは配列番号23、26、29、32又は35それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号24、配列番号27、配列番号30、配列番号33又は配列番号36に示すアミノ酸配列、あるいは配列番号24、27、30、33又は36それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、抗体又は抗体断片を有効成分として含む、前項1~6のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
8.重鎖可変領域1(CDR H1)が、配列番号7、あるいは配列番号7に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号8、あるいは配列番号8に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号9、あるいは配列番号9に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号22、あるいは配列番号22に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号23、あるいは配列番号23に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号24、あるいは配列番号24に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、前項7に記載の炎症性肺疾患の予防及び/又は治療剤。
9.重鎖可変領域1(CDR H1)が、配列番号10、あるいは配列番号10に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号11、あるいは配列番号11に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号12、あるいは配列番号12に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号25、あるいは配列番号25に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号26、あるいは配列番号26に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号27、あるいは配列番号27に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、前項7に記載の炎症性肺疾患の予防及び/又は治療。
10.重鎖可変領域1(CDR H1)が、配列番号13、あるいは配列番号13に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号14、あるいは配列番号14に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号15、あるいは配列番号15に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号28、あるいは配列番号28に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号29、あるいは配列番号29に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号30、あるいは配列番号30に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、前項7に記載の炎症性肺疾患の予防及び/又は治療剤。
11.重鎖可変領域1(CDR H1)が、配列番号16、あるいは配列番号16に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号17、あるいは配列番号17に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号18、あるいは配列番号18に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号31、あるいは配列番号31に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号32、あるいは配列番号32に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号33、あるいは配列番号33に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、前項7に記載の炎症性肺疾患の予防及び/又は治療剤。
12.重鎖可変領域1(CDR H1)が、配列番号19、あるいは配列番号19に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号20、あるいは配列番号20に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号21、あるいは配列番号21に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号34、あるいは配列番号34に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号35、あるいは配列番号35に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号36、あるいは配列番号36に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、前項7に記載の炎症性肺疾患の予防及び/又は治療剤。
13.S100A8及び/又はS100A9と、その受容体であるRAGEとの相互作用を遮断し、RAGEの下流にある転写因子であって、炎症性サイトカインの発現を誘導するNF-κBの発現及び肺線維芽細胞の増殖を抑制するとともに、活性化線維芽細胞の増殖を抑制し、更には、活性化線維芽細胞の筋線維芽細胞への分化を抑制することを特徴とする、前項1~12のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
14.COVID-19の予防及び/又は治療剤としての、前項1~13のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
本参考例では、以降の実施例で示す抗S100A8/A9抗体作製のための抗原としてのS100A8/A9ヘテロダイマーの調製について説明する。S100A8/A9ヘテロダイマーは、pET21へ全長S100A8及び全長S100A9を組みこんだ発現ベクター(図1参照)を用いて大腸菌により作製し、精製した(Futami J. et al., Biochem Biophys Rep., 19; 6: 94-100, (2016)参照)。比較例のために、全長S100A8又は全長S100A9をpET21へ組込み、上記と同手法により大腸菌により作製し、精製した(Futami J. et al. (2016)参照)。
本実施例では、以下の実施例及び実験例で使用する抗S100A8/A9モノクローナル抗体の作製について説明する。本実施例の抗S100A8/A9モノクローナル抗体は、上記(参考例1)で調製したS100A8/A9ヘテロダイマーを抗原として作製した。
本実施例の抗S100A8/A9モノクローナル抗体は、上記(参考例1)で調製したS100A8/A9ヘテロダイマーを抗原とし、モノクローナル抗体受託サービス、ジェノスタッフ(日本ジェネティクス)を利用して作製した。免疫動物はマウス(BALB/c)を用い、抗原の免疫にはTiter-MAXをアジュバンドとして用いた。従来法に従い免疫動物の脾臓とマウスミエローマ細胞(P3U1)を、ポリエチレングリコール(PEG1500)を用いて融合させ、ハイブリドーマを作製し、160クローンを得た。
上記得られた160クローンのハイブリドーマから、S100A8/A9ヘテロダイマー、S100A8又はS100A9を固相化してELISAスクリーニングを行ない、図5に示す10クローンを選抜した。選抜したS100A8/A9中和抗体(図5に示す「α-S100A8/A9 antibody」)候補を発現するハイブリドーマを無血清培養へ馴化し、in vitro及びin vivo実験のために大量調製した。各クローンの培養上清を回収し、Protein Gカラムにより精製を行い、すべてのクローンについて数ミリグラムのタンパク質を調製した。CBB染色による純度検定を行ったところ、目的タンパク質以外のバンドは全く検出されず、高純度で精製抗体が調製されていることを確認した。
本実施例では実施例1で作製して選抜した160クローンのハイブリドーマから産生されるモノクローナル抗体について、S100A8/A9誘導性炎症性サイトカインの産生量に及ぼす影響を確認した。S100A8/A9により強く炎症性サイトカインが誘導されるヒトケラチノサイトを用いて、各抗体のS100A8/A9シグナルの抑制効果を炎症性サイトカインのmRNA発現量を指標に評価した。具体的には、30 ng/mLの精製S100A8/A9と160クローンのハイブリドーマ培養上清1 mLからProtein Gカラムにより精製した各抗S100A8/A9モノクローナル抗体をケラチノサイト(Normal Human Keratinocytes: NHK)へ添加し、37℃、3時間培養後の細胞を回収し、TNF-α、IL-6、IL-8の各mRNA発現量をリアルタイム定量PCR(qPCR)解析を行った。
TNFα測定用 Fwd:GACAAGCCTGTAGCCCATGT(配列番号1)
Rev:TCTCAGCTCCACGCCATT(配列番号2)
IL-6測定用 Fwd:CTTCCCTGCCCCAGTACC(配列番号3)
Rev:CTGAAGAGGTGAGTGGCTGTC(配列番号4)
IL-8測定用 Fwd:AGACAGCAGAGCACACAAGC(配列番号5)
Rev:AGGAAGGCTGCCAAGAGAG(配列番号6)
上記スクリーニングより選別した5種の抗S100A8/A9モノクローナル抗体(クローンNo.:45,85,235,258及び260)について、重鎖及び軽鎖の可変領域の配列を解析した。
VH-CDR
クローンNo.45:CDR H1 :SYWMQ (配列番号7)
クローンNo.45:CDR H2 :AIYPGDGDTRDTQKFKG (配列番号8)
クローンNo.45:CDR H3 :MAGYNYDNDY(配列番号9)
クローンNo.85:CDR H1 :SGYNWH (配列番号10)
クローンNo.85:CDR H2 :YIQYSGSTNYNPSLKS (配列番号11)
クローンNo.85:CDR H3 :ALRYDYSWFAY(配列番号12)
クローンNo.235:CDR H1 :NFWMN(配列番号13)
クローンNo.235:CDR H2 :QIYPGKSDTNYNGKFKG (配列番号14)
クローンNo.235:CDR H3 :WGAYYKYGGSYFDY(配列番号15)
クローンNo.258:CDR H1 :TASMGVS (配列番号16)
クローンNo.258:CDR H2 :HIYWDDDKRYNPSLKS (配列番号17)
クローンNo.258:CDR H3 :RPLGYFDV(配列番号18)
クローンNo.260:CDR H1 :NYGVH(配列番号19)
クローンNo.260:CDR H2 :VVWAGGSTNYNSALMS (配列番号20)
クローンNo.260:CDR H3 :ARDYYGYDGYFGA(配列番号21)
VL-CDR
クローンNo.45:CDR L1 :KASQDINKYIA (配列番号22)
クローンNo.45:CDR L2 :YTSTLQP (配列番号23)
クローンNo.45:CDR L3 :LQYDNLRT(配列番号24)
クローンNo.85:CDR L1 :KASQDVSTAVA (配列番号25)
クローンNo.85:CDR L2 :SASYRYT (配列番号26)
クローンNo.85:CDR L3 :QQHYSTPLT(配列番号27)
クローンNo.235:CDR L1 :SASQGISNYLN(配列番号28)
クローンNo.235:CDR L2 :YTSSLHS (配列番号29)
クローンNo.235:CDR L3 :QQYSKFPYT(配列番号30)
クローンNo.258:CDR L1 :KASQDINNYIS (配列番号31)
クローンNo.258:CDR L2 :YTSTLQP (配列番号32)
クローンNo.258:CDR L3 :LQYDNLLWT(配列番号33)
クローンNo.260:CDR L1 :KASQDINSYLT (配列番号34)
クローンNo.260:CDR L2 :RANRLVD (配列番号35)
クローンNo.260:CDR L3 :LQYDEFPLT(配列番号36)
本実施例では、抗S100A8/A9モノクローナル抗体(クローンNo.45)のFabドメインにヒト IgG2-Fc部分を融合させたキメラ抗体を作製した。抗S100A8/A9モノクローナル抗体(クローンNo.45)の重鎖及び軽鎖の可変領域の配列解析・CDR解析し、Human IgG2の可変領域と組換えた配列を組み込んだCHO細胞用安定発現ベクターを作製し、ヒト IgG2-Fc部分の遺伝子を組み合わせてCHO細胞に形質導入し、安定的に抗S100A8/A9キメラ抗体を作製した(図7参照)。抗体は、国際公開第WO2017/061354号に記載の方法により作製した。
肺線維症の原因の一つとして、線維芽細胞の異常増殖があげられる。そこでS100A8/A9依存的な線維芽細胞の増殖について検討した。B6マウス(野生型:WT)及びS100A8/A9の肺での主要な受容体であるRAGEをノックアウトしたB6マウス(RAGE-/-)由来の胎児線維芽細胞(Mouse Embryo Fibroblasts: MEF)の、S100A8/A9添加による増殖亢進をEdU(5-ethynil-2'-deoxyuridine)染色法により確認した(図8参照)。ヒト胎児正常肺組織由来線維芽細胞(Human Lung Fibroblasts)MRC-5細胞の、S100A8/A9添加による増殖亢進を同様にEdU染色法により確認した(図9参照)。具体的には以下の方法で確認した。まず、10%ウシ胎児血清(FBS)含有GIBCO(R) DMEM/F-12(Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12)培地で培養した線維芽細胞を、各々6ウェルプレートへ2×105 cells/wellで播種した。培養24時間後に無血清培地に交換した。さらに24時間培養後、0.5%FBS含有培地に交換し、各濃度のS100A8/A9を添加した。さらに5時間培養後にEdUを添加し、1時間後にEdUで染色された細胞を顕微鏡で確認した。図8及び図9に示すとおり、S100A8/A9の添加により、S100A8/A9濃度が100 ng/mLまで増殖亢進が確認され、1000 ng/mLでは増殖速度が減弱した。
S100A8/A9受容体であるRAGEの下流に存在する転写因子NF-κBは、その活性化により様々な炎症性サイトカインの発現を誘導する。線維芽細胞におけるS100A8/A9依存的なNF-κBシグナルの活性化を評価するため、NF-κBとBiotin標識NF-κB結合DNAプローブとの相互作用の検出をゲルシフトアッセイ(electrophoretic mobility shift assay: EMSA)を用いて行った。次に、S100A8/A9で誘導されたNF-κBに対する抗S100A8/A9抗体の作用を、同様にゲルシフトアッセイにより確認した。
肺線維症の病態において、活性化線維芽細胞の筋線維芽細胞への分化は、それに伴いコラーゲンや細胞外マトリックス成分の過剰沈着を誘導し、肺線維化を悪化させる。特発性肺線維症(IPF)の治療薬として認可されているニンテダニブは、線維芽細胞の増殖及び筋線維芽細胞への分化を阻害する。そこでS100A8/A9が線維芽細胞から筋線維芽細胞への分化を誘導するリスク因子であることを筋線維芽細胞のマーカーであるα-SMA(α-smooth muscle actin)の発現により確認し、α-SMA発現に対する抗S100A8/A9抗体の作用を確認した。
ブレオマイシン誘発肺線維症モデルにおける抗S100A8/A9抗体での肺傷害抑制効果を確認した。図14に示すプロトコールに従い、各群7匹のC57BL/6J雌(8週齢)の気管内へマウスの体重当たり1.0 mg/kgのブレオマイシンを含むPBSを50μl投与し、肺傷害モデルマウスを作製した。ブレオマイシン投与後1~2時間後にPBSバッファー(コントロール群:0μg)、又は200μg及び500μgの抗S100A8/A9抗体を尾静脈内投与した。
実施例8に示すとおり、抗S100A8/A9抗体は、肺線維症に対して優れた治療効果を示す知見を得た。引き続き、本発明者らは抗S100A8/A9抗体の更なる薬理学的作用について検討する中、呼吸器上皮に発現している宿主のタンパク分解酵素の一つであるTMPRSS2が、SARS-CoV-2の感染において重要なタンパク質の1つであることに着眼し、抗S100A8/A9抗体がTMPRSS2発現に及ぼす影響について調べた。すなわち、ヒト肺細胞を用いて、S100A8/A9タンパク質依存的なTMPRSS2発現変化及び抗S100A8/A9抗体として抗S100A8/A9モノクローナル抗体(クローンNo.45)を用いて、抗S100A8/A9抗体がTMPRSS2発現に及ぼす影響について調べた。
Fwd : GATGACAGCGGATCCACCAG(配列番号38)
Rev : CCGCAGGCTATACAGCGTAA(配列番号39)
Claims (14)
- S100A8及びS100A9タンパク質のヘテロダイマーに対して抗原結合活性を有する抗体又は抗体断片を有効成分として含む炎症性肺疾患の予防及び/又は治療剤。
- 抗体又は抗体断片が、S100A8モノマーに対する抗原結合活性よりも高い抗原結合活性を有することを特徴とする、請求項1に記載の炎症性肺疾患の予防及び/又は治療剤。
- 抗体又は抗体断片が、S100A8及びS100A9のヘテロダイマーに対し、抗原結合活性を有し、S100A8モノマー及び/又はS100A9モノマーとは抗原結合活性を有さない、請求項1又は2に記載の炎症性肺疾患の予防及び/又は治療剤。
- 抗原結合活性が中和親和性である、請求項1~3のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
- 抗体又は抗体断片が、モノクローナル抗体又はモノクローナル抗体断片である、請求項1~4のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
- モノクローナル抗体のサブクラスが、IgG1、IgG2、IgG3及びIgG4より選択されるいずれかである、請求項5に記載の炎症性肺疾患の予防及び/又は治療剤。
- 抗体又は抗体断片が、重鎖可変領域1(CDR H1)、重鎖可変領域2(CDR H2)及び重鎖可変領域3(CDR H3)を含む重鎖可変領域と、軽鎖可変領域1(CDR L1)、軽鎖可変領域2(CDR L2)及び軽鎖可変領域3(CDR L3)を含む軽鎖可変領域を含み、
重鎖可変領域1(CDR H1)が、配列番号7、配列番号10、配列番号13、配列番号16又は配列番号19に示すアミノ酸配列、あるいは配列番号7、10、13、16又は19それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号8、配列番号11、配列番号14、配列番号17又は配列番号20に示すアミノ酸配列、あるいは配列番号8、11、14、17又は20それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号9、配列番号12、配列番号15、配列番号18又は配列番号21に示すアミノ酸配列、あるいは配列番号9、12、15、18又は21それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号22、配列番号25、配列番号28、配列番号31又は配列番号34に示すアミノ酸配列、あるいは配列番号22、25、28、31又は34それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号23、配列番号26、配列番号29、配列番号32又は配列番号35に示すアミノ酸配列、あるいは配列番号23、26、29、32又は35それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号24、配列番号27、配列番号30、配列番号33又は配列番号36に示すアミノ酸配列、あるいは配列番号24、27、30、33又は36それぞれにつき、1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、抗体又は抗体断片を有効成分として含む、請求項1~6のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。 - 重鎖可変領域1(CDR H1)が、配列番号7、あるいは配列番号7に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号8、あるいは配列番号8に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号9、あるいは配列番号9に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号22、あるいは配列番号22に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号23、あるいは配列番号23に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号24、あるいは配列番号24に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、請求項7に記載の炎症性肺疾患の予防及び/又は治療剤。 - 重鎖可変領域1(CDR H1)が、配列番号10、あるいは配列番号10に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号11、あるいは配列番号11に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号12、あるいは配列番号12に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号25、あるいは配列番号25に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号26、あるいは配列番号26に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号27、あるいは配列番号27に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、請求項7に記載の炎症性肺疾患の予防及び/又は治療。 - 重鎖可変領域1(CDR H1)が、配列番号13、あるいは配列番号13に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号14、あるいは配列番号14に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号15、あるいは配列番号15に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号28、あるいは配列番号28に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号29、あるいは配列番号29に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号30、あるいは配列番号30に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、請求項7に記載の炎症性肺疾患の予防及び/又は治療剤。 - 重鎖可変領域1(CDR H1)が、配列番号16、あるいは配列番号16に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号17、あるいは配列番号17に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号18、あるいは配列番号18に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号31、あるいは配列番号31に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号32、あるいは配列番号32に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号33、あるいは配列番号33に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、請求項7に記載の炎症性肺疾患の予防及び/又は治療剤。 - 重鎖可変領域1(CDR H1)が、配列番号19、あるいは配列番号19に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域2(CDR H2)が、配列番号20、あるいは配列番号20に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
重鎖可変領域3(CDR H3)が、配列番号21、あるいは配列番号21に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域1(CDR L1)が、配列番号34、あるいは配列番号34に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域2(CDR L2)が、配列番号35、あるいは配列番号35に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含み、
軽鎖可変領域3(CDR L3)が、配列番号36、あるいは配列番号36に示すアミノ酸配列において1若しくは複数個のアミノ酸が欠失、付加、置換、又は挿入されてなるアミノ酸配列のいずれかを含む、請求項7に記載の炎症性肺疾患の予防及び/又は治療剤。 - S100A8及び/又はS100A9と、その受容体であるRAGEとの相互作用を遮断し、RAGEの下流にある転写因子であって、炎症性サイトカインの発現を誘導するNF-κBの発現及び肺線維芽細胞の増殖を抑制するとともに、活性化線維芽細胞の増殖を抑制し、更には、活性化線維芽細胞の筋線維芽細胞への分化を抑制することを特徴とする、請求項1~12のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
- COVID-19の予防及び/又は治療剤としての、請求項1~13のいずれかに記載の炎症性肺疾患の予防及び/又は治療剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021553474A JPWO2021085252A1 (ja) | 2019-10-30 | 2020-10-20 | |
CN202080071786.XA CN114555119A (zh) | 2019-10-30 | 2020-10-20 | 炎症性肺疾病的预防和/或治疗剂 |
US17/768,865 US20230144545A1 (en) | 2019-10-30 | 2020-10-20 | Prophylactic and/or therapeutic agent for inflammatory pulmonary disease |
AU2020376350A AU2020376350A1 (en) | 2019-10-30 | 2020-10-20 | Prophylactic and/or therapeutic agent for inflammatory pulmonary disease |
EP20882559.6A EP4052725A1 (en) | 2019-10-30 | 2020-10-20 | Prophylactic and/or therapeutic agent for inflammatory pulmonary disease |
CA3155346A CA3155346A1 (en) | 2019-10-30 | 2020-10-20 | Prophylactic and/or therapeutic agent for inflammatory pulmonary disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-197222 | 2019-10-30 | ||
JP2019197222 | 2019-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021085252A1 true WO2021085252A1 (ja) | 2021-05-06 |
Family
ID=75714496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/039460 WO2021085252A1 (ja) | 2019-10-30 | 2020-10-20 | 炎症性肺疾患の予防及び/又は治療剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230144545A1 (ja) |
EP (1) | EP4052725A1 (ja) |
JP (1) | JPWO2021085252A1 (ja) |
CN (1) | CN114555119A (ja) |
AU (1) | AU2020376350A1 (ja) |
CA (1) | CA3155346A1 (ja) |
WO (1) | WO2021085252A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023007182A1 (en) * | 2021-07-29 | 2023-02-02 | The University Of Birmingham | Protein interaction inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11858984B2 (en) | 2018-04-27 | 2024-01-02 | National University Corporation Okayama University | Anti-S100A8/A9 antibody and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015177367A1 (en) | 2014-05-23 | 2015-11-26 | Active Biotech Ab | Novel compounds useful as s100-inhibitors |
WO2017061354A1 (ja) | 2015-10-06 | 2017-04-13 | 国立大学法人 岡山大学 | 遺伝子発現用カセット及びその産生物 |
JP2019197222A (ja) | 2013-01-21 | 2019-11-14 | ドルビー ラボラトリーズ ライセンシング コーポレイション | プログラム・ラウドネスおよび境界メタデータをもつオーディオ・エンコーダおよびデコーダ |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190367600A1 (en) * | 2017-01-27 | 2019-12-05 | A-Clip Institute, Co., Ltd. | Prophylactic and/or therapeutic agent of infectious diseases or inflammatory diseases |
-
2020
- 2020-10-20 WO PCT/JP2020/039460 patent/WO2021085252A1/ja active Search and Examination
- 2020-10-20 JP JP2021553474A patent/JPWO2021085252A1/ja active Pending
- 2020-10-20 CA CA3155346A patent/CA3155346A1/en active Pending
- 2020-10-20 CN CN202080071786.XA patent/CN114555119A/zh active Pending
- 2020-10-20 EP EP20882559.6A patent/EP4052725A1/en active Pending
- 2020-10-20 US US17/768,865 patent/US20230144545A1/en active Pending
- 2020-10-20 AU AU2020376350A patent/AU2020376350A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019197222A (ja) | 2013-01-21 | 2019-11-14 | ドルビー ラボラトリーズ ライセンシング コーポレイション | プログラム・ラウドネスおよび境界メタデータをもつオーディオ・エンコーダおよびデコーダ |
WO2015177367A1 (en) | 2014-05-23 | 2015-11-26 | Active Biotech Ab | Novel compounds useful as s100-inhibitors |
WO2017061354A1 (ja) | 2015-10-06 | 2017-04-13 | 国立大学法人 岡山大学 | 遺伝子発現用カセット及びその産生物 |
Non-Patent Citations (8)
Title |
---|
EHLERMANN PHILIPP; EGGERS KAI; BIERHAUS ANGELIKA; MOST PATRICK; WEICHENHAN DIETER; GRETEN JOHANNES; NAWROTH PETER P; KATUS HUGO A;: "Increased proinflammatory endothelial response to S 100A8 /A9 after preactivation through advanced glycation end products", CARDIOVASC DIABETOLOGY, vol. 5, 2006, XP021017756, DOI: 10.1186/1475-2840-5-6 * |
FUTAMI J ET AL., BIOCHEM BIOPHYS REP., vol. 19, no. 6, 2016, pages 94 - 100 |
G. HARDISTY, S. LAW, J. GILLAN, E. G. FINDLAY, S. VERMEREN, D. DAVIDSON, R. GRAY: "WS08-1 Calprotectin: the cystic fibrosis antigen regulates neutrophil migration during experimental lung inflammation and is a novel therapeutic target in cystic fibrosis", JOURNAL OF CYSTIC FIBROSIS, vol. 18, no. Suppl.1, 31 January 2019 (2019-01-31), pages S14, XP055822768 * |
GAGANDEEP KAUR, GIUSEPPE LUNGARELLA & IRFAN RAHMAN: "SARS-CoV-2 COVID-19 susceptibility and lung inflammatory 14 storm by smoking and vaping", JOURNAL OF INFLAMMATION, vol. 17, 21, 10 June 2020 (2020-06-10), pages 1 - 8, XP055822778 * |
KINOSHITA, R. ET AL.: "Newly developed anti- S 100A8 /A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis", INT J CANCER, vol. 145, no. 2, 31 July 2019 (2019-07-31), pages 569 - 575, XP055646105, DOI: 10.1002/ijc.31982 * |
LI MA ET AL., INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 40, 2017, pages 31 - 38 |
LUTZ WOLLINL ET AL., EUROPEAN RESPIRATORY JOURNAL, 2015 |
MARGARITOPOULOS ET AL., BMC PULMONARY MEDICINE, vol. 18, 2018, pages 177 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023007182A1 (en) * | 2021-07-29 | 2023-02-02 | The University Of Birmingham | Protein interaction inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP4052725A1 (en) | 2022-09-07 |
US20230144545A1 (en) | 2023-05-11 |
AU2020376350A1 (en) | 2022-05-26 |
CN114555119A (zh) | 2022-05-27 |
JPWO2021085252A1 (ja) | 2021-05-06 |
CA3155346A1 (en) | 2021-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6116652B2 (ja) | 破骨細胞関連蛋白質Siglec−15を標的とした抗体 | |
KR101317264B1 (ko) | 톨 유사 수용체 3 길항제, 방법 및 용도 | |
JP6671069B2 (ja) | 炎症性疾患の予防又は治療剤 | |
WO2021085252A1 (ja) | 炎症性肺疾患の予防及び/又は治療剤 | |
JP2017512479A (ja) | Lgr5に結合するヒト化抗体 | |
US20090191211A1 (en) | METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | |
KR20150010919A (ko) | 항 TNF-α/CXCL10 이중 타겟 항체 및 그의 용도 | |
JP2020059743A (ja) | 血管内皮リパーゼの酵素活性を阻害するヒト化モノクローナル抗体 | |
US20230374090A1 (en) | Liver-specific wnt signal enhancing molecules and uses thereof | |
AU2015392603B2 (en) | Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif | |
JP7392951B2 (ja) | 抗s100a8/a9抗体とその用途 | |
JP6195306B2 (ja) | Elの酵素活性を阻害するelに対するモノクローナル抗体 | |
TW202237180A (zh) | 炎症性疾病的預防劑和/或治療劑 | |
WO2012043747A1 (ja) | グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤 | |
JP6304775B2 (ja) | 血管内皮リパーゼの酵素活性を阻害するモノクローナル抗体 | |
US20160326246A1 (en) | Method for Regulating Cell Proliferation | |
JP2019099492A (ja) | 抗ヒトil−26抗体 | |
WO2023020624A1 (en) | Use of alpha-enolase antagonist in treating fibrotic diseases | |
CN114686429A (zh) | 一种激活nk细胞的肿瘤免疫治疗方法 | |
JP2011177128A (ja) | ショウジョウバエ由来生理活性ペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20882559 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2021553474 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3155346 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020376350 Country of ref document: AU Date of ref document: 20201020 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020882559 Country of ref document: EP Effective date: 20220530 |